Lipid-lowering drugs: present and future

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hyperlipidemia is one of the most important risk factors for the development atherosclerotic cardiovascular diseases. The review summarizes data on lipoprotein metabolism and discusses methods pharmacological correction of dyslipidemia. Classification presented Lipid-lowering drugs, pharmacodynamics and pharmacokinetic features, indications for use and side effects of individual representatives, issues of their effectiveness and safety are considered. Prospects for the treatment of dyslipidemia are outlined.

Full Text

Restricted Access

About the authors

Natalia O. Selizarova

Saint Petersburg State Chemical-Pharmaceutical University

Author for correspondence.
Email: natalia.selizarova@pharminnotech.com
ORCID iD: 0000-0003-4826-2416
SPIN-code: 6415-5003

MD, Cand. Sci. (Medicine)

Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376

Svetlana M. Napalkova

Saint Petersburg State Chemical-Pharmaceutical University

Email: svetlana.napalkova@pharminnotech.com
ORCID iD: 0000-0002-9216-8673
SPIN-code: 7311-2841

Dr. Sci. (Biology), Professor

Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376

Natalia A. Anisimova

Saint Petersburg State Chemical-Pharmaceutical University

Email: natalia.anisimova@pharminnotech.com
ORCID iD: 0000-0002-2620-2976
SPIN-code: 8747-6166

Cand. Sci. (Biology), Assistant Professor

Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376

Olga V. Buyuklinskaya

Saint Petersburg State Chemical-Pharmaceutical University

Email: olga.buyklinskaya@pharminnotech.com
ORCID iD: 0000-0002-4453-1079
SPIN-code: 9691-6490

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376

Vera Ts. Bolotova

Saint Petersburg State Chemical-Pharmaceutical University

Email: vera.bolotova@pharminnotech.com
ORCID iD: 0000-0001-7559-186X
SPIN-code: 5035-2066

Cand. Sci. (Pharmacy), Assistant Professor

Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376

Sergey V. Okovityi

Saint Petersburg State Chemical-Pharmaceutical University

Email: sergey.okovity@pharminnotech.com
ORCID iD: 0000-0003-4294-5531
SPIN-code: 7922-6882

Dr. Sci. (Medicine), Professor

Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376

References

  1. Oksenoit GK, Nikitin SY, editors. Health care in Russia. Statistical collection. Moscow: Rosstat; 2017. 170 p. (In Russ.)
  2. Sergienko IV, Nedogoda CV, Vertkin AL, et al. Actual issues of increasing the availability of innovative therapy and organization of medical care for patients with atherosclerotic cardiovascular diseases in the Russian Federation. Council of experts. Journal of Atherosclerosis and Dyslipidemias. 2022;(49):54–61. (In Russ.) EDN: CVUPPX doi: 10.34687/2219-8202.JAD.2022.04.0006
  3. Golan DE, Armstrong EJ, Armstrong AW, editors. Principles of pharmacology: the pathophysiologic basis of drug therapy: fourth Edition. Elsevier: 2017. P. 1042.
  4. Chaulin AM. New groups of hypolipidemic medications based on inhibition of proprotein convertase subtilisin/kexin type 9 (pcsk9). Part 1. Clinical Medicine. 2020;98(11–12):739–744. EDN: JXHPIA doi: 10.30629/0023-2149-2020-98-11-12-12-739-744
  5. Borodulin VI, Topoliansky AV. To the scientific results of the twentieth century: the role of domestic researchers in the development of atherosclerosis. Clinical Medicine. 2013;91(11):70–73. (In Russ.) EDN: RSHRUP
  6. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5
  7. Karpov YuA. The efficacy and safety of statin therapy. Atmosphere. Cardiology News. 2019;(1):3–12. EDN: GRIGYR
  8. Chaulin AM. The main side effects of statins in clinical practice. Clinical Practice. 2022;13(2):98–107. EDN: QHSXST doi: 10.17816/clinpract108076
  9. Makhatova AR, Tuleutaeva RE. Dangerous and undesirable drug interactions of statins in patients with cardiovascular disease. Science & Health Care. 2019;21(2):55–56. EDN: ZKVNBB
  10. Sumarokov AB, Kukharchuk VV. Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia. Therapeutic Archive. 2014;86(12): 107–115. EDN: RNYIIS doi: 10.17116/terarkh20148612107-115
  11. Lawitz EJ, Bhandari BR, Ruane PJ, et al. Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin Gastroenterol Hepatol. 2023;21(1): 143–152.e3. doi: 10.1016/j.cgh.2021.12.044
  12. Shaposhkin AI, Genkel VV. Pleiotropic effects of ezetimibe. Cardiology. 2019;59(12):12–17. EDN: ZIIFEL doi: 10.18087/cardio.n875
  13. Gurevich VS, Solodovnikov AG, Manko KS, et al. The efficacy of ezetimibe and statin combination therapy compared to statin monotherapy: a systematic review and meta-analysis of observational trials. Atmosphere. Cardiology News. 2023;(3):33–46. EDN: PFTAPH doi: 10.24412/2076-4189-2023-13015
  14. Robinson JG, Rogers WJ, Nedergaard BS, et al. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014;37(4):195–203. doi: 10.1002/clc.22252
  15. Schneider KO, Maksimov ML, Baranova VA, et al. PCSK9 inhibitor therapy as an alternative for statin intolerance. Safety and Risk of Pharmacotherapy. 2023;11(4):442–449. EDN: OZZYFX doi: 10.30895/2312-7821-2023-366
  16. Vatutin NT, Taradin GG, Rakitskaya IV, et al. Hypolipidemic therapy in insufficient efficacy or intolerance of statins (literature review). Bulletin of Emergency and Restorative Therapy. 2020;5(4):29–39. EDN: VPAHIT
  17. O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109–1119. doi: 10.1161/CIRCULATIONAHA.122.061620
  18. Santos RD, Ruzza A, Hovingh GK, et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022;10(10):732–740. doi: 10.1016/S2213-8587(22)00221-2
  19. Ezhov MV, Kukharchuk VV. Disorders of lipid metabolism. Clinical guidelines 2023. Russian Cardiology Journal. 2023;28(5):54–71. EDN: YVZOWJ doi: 10.15829/1560-4071-2023-5471
  20. Voyevoda MI, Gurevich VS, Ezhov MV, et al. Inclisiran — a new era in lipid-lowering therapy. Cardiology. 2022;62(6):57–62. EDN: NEWLUX doi: 10.18087/cardio.2022.6.n2115
  21. Jain P. Traditional and novel non-statin lipid-lowering drugs. Indian Heart J. 2024;76(Suppl 1):S38–S43. doi: 10.1016/j.ihj.2023.11.003
  22. Petrosyan AS, Rud RS, Polyakov PP, et al. The pathogenetic basis of the action of bempedoic acid. Rational Pharmacotherapy in Cardiology. 2022;18(6):734–741. EDN: HLENQU doi: 10.20996/1819-6446-2022-12
  23. Tummala R, Gupta M, Devanabanda AR, et al. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis. Annals of Medicine. 2022;54(1):1287–1296. EDN: RAOOHE doi: 10.1080/07853890.2022.2059559
  24. Banach M, Duell PB, Gotto AM Jr, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5(10):1124–1135. doi: 10.1001/jamacardio.2020.2314
  25. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–1032. doi: 10.1056/NEJMoa1803917

Copyright (c) 2024 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.